• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tandem Diabetes Care to acquire patch pump maker AMF Medical

December 13, 2022 By Sean Whooley

Tandem Diabetes Care AMF Medical Sigi insulin diabetes patch pump
The Sigi insulin patch pump. [Image courtesy of Tandem Diabetes Care/AMF Medical]
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it acquired AMF Medical, maker of the Sigi patch pump for insulin delivery.

Switzerland-based AMF Medical currently develops the Sigi patch pump and does not offer it commercially. The system received FDA breakthrough device designation just over one year ago.

AMF Medical designed Sigi as an ergonomic, rechargeable patch pump for reducing the burden of diabetes management. It uses pre-filled insulin cartridges and offers compatibility with automated insulin delivery technology.

The acquisition represents the second major buy in 2022 for Tandem. In July, the company bought extended wear infusion set developer Capillary Biomedical.

“This acquisition supports our commitment to drive growth through innovation, as AMF Medical has novel technology and a shared passion for creating easy-to-use solutions to improve the lives of people with diabetes,” said John Sheridan, Tandem Diabetes Care president and CEO. “Our portfolio approach to diabetes care is designed to bring the benefits of advanced insulin pump therapy to more people worldwide, utilize our expertise in automated insulin delivery technology and data management, and leverage our commercial infrastructure to create shareholder value.”

Terms of the deal

The acquisition features a number of payments that include investments and milestones.

It begins with a strategic investment paid by Tandem in the third quarter of 2022. That investment totaled more than $8.6 million, or Swiss Francs (“CHF”) 8 million.

Tandem owes a cash payment of approximately $67.4 million (CHF 62.4 million) at closing. Additional contingent earnout payments could reach $140 million (CHF 129.6 million). That includes up to $41.5 million (CHF 38.4 million) upon successful development milestone completion over two years.

Additionally, Tandem agreed to pay up to $98.5 million (CHF 91.2 million) upon obtaining FDA clearance for an automated controller-enabled (ACE) pump.

Tandem expects the transaction to close in January 2023.

Benefits of the deal for Tandem

The company said AMF Medical’s technology represents a “proprietary and disruptive” insulin delivery solution.

It could expand Tandem’s type 1 and type 2 addressable market opportunities, the company said. The acquisition adds a pump designed for a segment of people not served by Tandem today.

Additionally, the deal accelerates time-to-market for a patch pump in Tandem’s portfolio. The company noted that adding a pump that minimizes the generation of electronic and battery waste enhances its sustainability objectives, too.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Technology Tagged With: AMF Medical, Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS